New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
October 31, 2014
05:57 EDTHLFHerbalife implied volatility of 106 at upper end of index mean range
Subscribe for More Information
October 30, 2014
17:10 EDTBMYOn The Fly: Closing Wrap
Stocks on Wall Street advanced, with a strong move higher from Visa (V) after its earnings report accounting for more than 100 points of the Dow's increase. The Nasdaq, which lagged all day, eventually moved off its lows and closed in positive territory as well. The New York Stock Exchange notified customers of a problem at 1:40 p.m., saying there was a “critical issue” and it was “experiencing issues publishing and receiving trades and quotes.” Ten minutes later, it sent a new alert saying the system was “processing trades and quotes normally.” ECONOMIC EVENTS: In the U.S., GDP grew 3.5% in the third quarter, topping the consensus forecast for 3.1% growth. Initial jobless claims rose 3K to 287K in the week ended October 25, which was narrowly above the 285K consensus estimate. COMPANY NEWS: Shares of credit card networks Visa (V) and MasterCard (MA) are rising after both companies reported stronger than expected results. Visa, which also authorized a new $5B share repurchase program and was upgraded to Outperform from Market Perform at FBR Capital, advanced $21.99, or 10.24%, to $236.65, while MasterCard gained $7.14, or 9.4%, to $83.13... Apple (AAPL) CEO Tim Cook publicly acknowledged in an essay published by Bloomberg Businessweek that he is gay. Cook noted that he feels "if hearing that the CEO of Apple is gay can help someone struggling to come to terms with who he or she is, or bring comfort to anyone who feels alone, or inspire people to insist on their equality, then it’s worth the trade-off with my own privacy." MAJOR MOVERS: Among the notable gainers was Bristol-Myers (BMY), which advanced $4.82, or 8.9%, to $58.98 after the company announced data for a trial of its Opdivo drug in certain lung cancer patients that a doctor involved in the study called "encouraging." Also higher was Omeros (OMER), which rose $4.99, or 43.09%, to $16.57 after the company announced it has received transitional pass-through status for its lead product, Omidria, from the Center for Medicare & Medicaid Services. Among the noteworthy losers was Glu Mobile (GLUU), which fell 92c, or 20.31%, to $3.61 after the game maker reported Q3 EPS that beat consensus but non-GAAP revenue that missed expectations. Also lower were shares of beauty products provider Avon (AVP), which fell 99c, or 9.03%, to $9.97 after its third quarter report. INDEXES: The Dow rose 221.11, or 1.3%, to 17,195.42, the Nasdaq gained 16.91, or 0.37%, to 4,566.14, and the S&P 500 added 12.35, or 0.62%, to 1,994.65.
15:02 EDTBMYLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
13:02 EDTBMYBristol-Myers, Lonza expand manufacturing agreement
Subscribe for More Information
12:59 EDTCGCarlyle JV seeks to buy more refining assets in Europe, Reuters reports
Subscribe for More Information
12:59 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTBMYBristol-Myers rallies after CheckMate -063 Opdivo study results
Subscribe for More Information
10:02 EDTCGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:04 EDTBMYBristol-Myers announces CheckMate -063 Opdivo study results
Bristol-Myers Squibb announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo With approximately 11 months of minimum follow up, the objective response rate was 15% as assessed by an independent review committee using RECIST 1.1 criteria and the median duration of response was not reached. The estimated one-year survival rate was 41% and median overall survival was 8.2 months.These data will be presented during the Plenary Session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology on October 31. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trademark for nivolumab.
07:55 EDTCGCarlyle Group story on track, says Oppenheimer
Subscribe for More Information
07:15 EDTPFE, BMYASCO / ASTRO / IASLC to hold symposium
Subscribe for More Information
06:12 EDTCGCarlyle Group downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Carlyle Group to Neutral following the Q3 report to reflect a mixed outlook.
06:06 EDTHLFHerbalife implied volatility of 106 at upper end of index mean range
Subscribe for More Information
05:49 EDTBMYStocks with implied volatility movement; ARCP BMY
Subscribe for More Information
October 29, 2014
16:58 EDTCGCarlyle Group files to sell 460K common units for holders
Subscribe for More Information
14:46 EDTPFEPfizer confirms FDA acclerated approval for TRUMENBA
Pfizer announced that the U.S. FDA has granted accelerated approval of TRUMENBA for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed. As part of the accelerated approval process, Pfizer will complete its ongoing studies to confirm the effectiveness of TRUMENBA against diverse serogroup B strains. TRUMENBA was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs.
14:03 EDTPFEFDA approves Trumenba vaccine for serogroup B Meningococcal disease
The FDA announced the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Trumenba was granted breakthrough therapy status, which is intended to expedite the development and review of medical products that address a serious or life-threatening condition. Trumenba is manufactured by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer.
08:31 EDTPFEPfizer publishes PRISTIQ clinical study
Subscribe for More Information
06:43 EDTCGCarlyle Group reports Q3 adjusted ENI 55c, consensus 54c
Subscribe for More Information
October 28, 2014
17:48 EDTHLFHerbalife launches new Green Tea Line
Subscribe for More Information
17:01 EDTPFEOn The Fly: Closing Wrap
Stocks on Wall Street opened in positive territory despite two disappointing economic data points and a mixed report from social media giant Twitter (TWTR). The market moved in a narrow range for the opening half hour of trading but gained upside momentum following a much better than expected consumer confidence reading. The market continued to tack on points throughout the afternoon and closed at its highs, led by the Nasdaq, which gained 1.75% for the session. ECONOMIC EVENTS: In the U.S., durable goods orders fell 1.3% in September, significantly undershooting expectations for them to have rise 0.7% in the month. The S&P Case-Shiller home price report showed prices were lower on a seasonally adjusted basis in the month of August compared to the prior month. A reading of consumer confidence surged to a seven-year high of 94.5 in October from a revised 89.0 final reading for September. The Richmond Fed's manufacturing index rose 6 points to 20 in October, beating expectations for it to have pulled back to 10. COMPANY NEWS: Twitter (TWTR) sunk $4.78, or 9.84%, to $43.78 after the social media company reported in-line profit and higher than expected Q3 revenue, but also reported a slowdown in user growth and provided weaker than expected Q4 guidance. Following last night's report, the stock was downgraded at RBC Capital, Nomura and Bank of America Merill Lynch to "Hold" or equivalent ratings, while Stifel lowered its rating on Twitter shares to Sell from Hold... Shares of Pfizer (PFE) edged up 6c, or 0.21%, to $29.09 after the pharmaceutical giant reported third quarter adjusted earnings per share and revenue that were a bit better than expected and narrowed its fiscal year profit outlook. Of note, Pfizer said during its earnings conference call that while proposed rule changes have made "inversions" more difficult, that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, gained 67c, or 0.95%, to $71.43 following Pfizer's comments. MAJOR MOVERS: Among the notable gainers following their earnings reports were Whirlpool (WHR), which advanced $10.66, or 6.77%, to $168.06, Cummins (CMI), which gained $9.22, or 6.81%, to $144.59, and Cliffs Natural (CLF), which jumped $2.05, or 22.19%, to $11.29. Among the noteworthy losers was Kohl’s (KSS), which dropped $3.89, or 6.64%, to $54.66 after the department store operator’s outlook for third quarter same store sales and fiscal 2014 profit missed expectations. Also lower were shares of Coach (COH), which fell $2.15, or 5.95%, to $34.00 after the luxury handbag and accessory maker reported sales declined 9% on a constant currency basis in its first quarter. INDEXES: The Dow rose 187.81, or 1.12%, to 17,005.75, the Nasdaq advanced 78.36, or 1.75%, to 4,564.29, and the S&P 500 gained 23.42, or 1.19%, to 1,985.05.
15:44 EDTCGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Southern Company (SO), consensus $1.07; Phillips 66 (PSX), consensus $1.75; Automatic Data Processing (ADP), consensus 60c; Praxair (PX), consensus $1.63; WellPoint (WLP), consensus $2.27; Exelon (EXC), consensus 73c; Eaton (ETN), consensus $1.23; Hess (HES), consensus $1.08; TE Connectivity (TEL), consensus $1.00; McGraw Hill Financial (MHFI), consensus 94c; Waste Management (WM), consensus 68c; Hershey (HSY), consensus $1.08; Ralph Lauren (RL), consensus $2.06; Wisconsin Energy (WEC), consensus 53c; Garmin (GRMN), consensus 71c; Sealed Air (SEE), consensus 46c; DENTSPLY (XRAY), consensus 60c; Goodyear Tire (GT), consensus 70c; Revlon (REV), one estimate 45c; Booz Allen (BAH), consensus 41c; Carlyle Group (CG), consensus 54c.
12:57 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:48 EDTPFEPfizer says reviewing options around two businesses
Subscribe for More Information
10:23 EDTPFEPfizer says still looking at deals based on strategic fit
Pfizer (PFE) said during its earnings conference call that uncertainty around future tax actions remain a concern, but that the company is still looking for M&A opportunities. Pfizer says proposed rule changes have made "inversions" more difficult, but that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, are up 1.3% to $71.69 as Pfizer's earnings conference call continues.
07:35 EDTPFEDURECT price target liowered to $1.50 from $2.50 at Stifel
Subscribe for More Information
07:22 EDTCGNYSSA to hold a conference
Subscribe for More Information
07:20 EDTCGTechAmerica Foundation to hold a conference
Subscribe for More Information
07:06 EDTPFEPfizer reports Q3 GEP sales down 6% operationally, GIP sales down 4%
Subscribe for More Information
07:05 EDTPFEPfizer narrows FY14 adjused EPS view to $2.23-$2.27 from $2.20-$2.30
Subscribe for More Information
07:04 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
Subscribe for More Information
07:03 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
07:01 EDTPFEPfizer reports Q3 adjusted EPS 57c, consensus 55c
Subscribe for More Information
October 27, 2014
20:54 EDTBMYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
16:36 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
15:36 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
15:18 EDTPFEEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
12:46 EDTPFEPfizer October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
08:15 EDTPFEPain Therapeutics to regain full rights to REMOXY
Subscribe for More Information
08:08 EDTPFEDURECT reports Pfizer to discontinue agreement with Pain Therapeutics
DURECT (DRRX) reported today that Pfizer (PFE) announced that it has notified Pain Therapeutics (PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
08:02 EDTPFEPfizer to discontinue agreement on REMOXY ER capsules CII
Pfizer Inc. (PFE) has notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics, Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics, Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date. Pfizer supports the appropriate use of opioid pain medications, and believes that abuse-deterrent products are important to help address the growing public health problem of opioid abuse in the U.S.
07:22 EDTPFEAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
16:02 EDTBMYOptions Update; October 24, 2014
Subscribe for More Information
11:15 EDTBMYBristol-Myers says has capacity for large deal
Subscribe for More Information
10:42 EDTBMYBristol-Myers sees coming in closer to high end of FY14 EPS guidance
Subscribe for More Information
10:10 EDTBMYBristol-Myers to host conference call
Conference call to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) will be held on October 31 at 2:30 pm. Webcast Link
07:35 EDTBMYBristol-Myers reports Q3 Eliquis revenue $216M
Reports Q3 Baraclude revenue $325M, Sprycel revenue $385M, Yervoy revenue $350M. Reports Q3 Abilify revenue $449M, Orencia revenue $444M.
07:33 EDTBMYBristol-Myers confirms FY14 adjusted EPS view $1.70-$1.80, consensus $1.78
Cuts FY14 GAAP EPS view to $1.15-$1.25 from $1.50-$1.60. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. Sees FY14 worldwide revenue $15.2B-$15.8B, consensus $15.58B. Also sees: Full-year gross margin as a percentage of revenues between 75% and 76%. Advertising and promotion expense decreasing in the mid-teen-digit range. Marketing, sales and administrative expenses decreasing in the mid-single-digit range. Research and development expenses growing in the mid-single-digit range. An effective tax rate of 19% - 20%.
07:31 EDTBMYBristol-Myers reports Q3 adjusted EPS 45c, consensus 42c
Subscribe for More Information
06:49 EDTPFEPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
05:54 EDTHLFStocks with implied volatility movement; NPSP HLF
Subscribe for More Information
October 23, 2014
18:52 EDTPFEOn The Fly: After Hours Movers
UP AFTER EARNINGS: Rubicon Project (RUBI), up 19.2%... KLA-Tencor (KLAC), up 15.8%... Gigamon (GIMO), up 13.5%... Maxwell (MXWL), up 11.3%... Qlik Technologies (QLIK), up 9.8%... NetSuite (N), up 5.5%... Microsoft (MSFT), up 3.3%... Juniper Networks (JNPR), reverses in after-hours trading and is up 1.4% after reporting third quarter results and announcing a $1.1B increase to the company's share repurchase authorization. ALSO HIGHER: Vitae Pharmaceuticals (VTAE), up 38.6% following positive top-line results from two Phase 1 clinical trials of BI1181181/VTP-37948... Pfizer (PFE), up 1.8% after announcing a new $11B share repurchase program. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.7%... Synaptics(SYNA), down 12.7%... Pandora (P), down 6.8%... Lattice Semiconductor (LSCC), down 5.6%... Maxim Integrated (MXIM), down 5.8%. ALSO LOWER: DryShips (DRYS), down 16.5% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 7.9% following PDUFA date for Natpara extended three months to January 24... GoPro (GPRO), down 2.8% after being initiated with an Underperform at Oppenheimer.
18:18 EDTPFEGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
16:17 EDTPFEPfizer announces new $11B share repurchase program
The board of directors also authorized a new $11B share repurchase program to be utilized over time. This new program is in addition to the $1.3B of authorization remaining under the company’s current share repurchase program.
15:39 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
08:15 EDTPFEPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
06:16 EDTCGPetSmart attracts interest from KKR, NY Post reports
Subscribe for More Information
October 22, 2014
13:37 EDTCGPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
12:55 EDTHLFPivotal analyst says Herbalife 'just not a pyramid scheme'
Pivotal Research analyst Tim Ramey said on CNBC that Herbalife "is just not a pyramid scheme."
October 21, 2014
18:33 EDTHLFIcahn reiterates view that high-yield market is a bubble
Says the Fed has given the economy, or the patient, "too much medicine." Says market should not be shorted. Again, says Apple (AAPL) CEO Tim is a "great CEO." Says Apple pay has a great future. Says Ebay (EBAY) is like his past campaign at Motorola. Reiterates view that Ebay should explore Paypal sale right now. Says Dell is on his radar screen. Says Warren Buffet sometimes too easy on companies, should do more on corporate governance. Again, says has never sold a share of Herbalife (HLF). Says Western Europe has "major problems," and continues to be short the Euro. Says energy stocks "getting cheap." Carl Icahn is speaking on Bloomberg TV.
07:15 EDTPFE, BMYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
11:00 EDTHLFHerbalife volatility increases
Subscribe for More Information
08:48 EDTHLFHerbalife initiated with a Buy at Pivotal Research
Subscribe for More Information
07:47 EDTPFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTBMYIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
05:54 EDTHLFStocks with implied volatility movement; HLD SD
Stocks with implied volatility movement; Herbalife (HLF) 109, SandRidge Energy (SD) 97 according to iVolatility.
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use